As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

As of January 17, 2023, 96.3 percent of adults in Ireland had been fully vaccinated against COVID-19. According to the manufacturers of the majority of COVID-19 vaccines currently in use in Europe, being fully vaccinated is when a person receives two doses of the vaccine. In Portugal, 94.2 percent of adults had received a full course of the COVID-19 vaccination, as well as 93.9 percent of those in Malta had been fully vaccinated. On the other hand, only 35.8 percent of adults in Bulgaria had been fully vaccinated.

Furthermore, the seven-day rate of cases across Europe shows which countries are currently worst affected by the situation. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

The number of COVID-19 vaccination doses administered per 100 people in Ireland rose to 221 as of Oct 27 2023. This dataset includes a chart with historical data for Ireland Coronavirus Vaccination Rate.

Please see FAQ for latest information on COVID-19 Data Hub Data Flows. https://covid-19.geohive.ie/pages/helpfaqs Category Field label Field Name Explanation

ExtractDate Extract Date Date the data is Extracted

Latitude Latitude

Longitude Longitude

VaccinationDate Vaccination Date Date the Vaccination occurred

Week Week Details of epidemiological weeks available here https://www.hpsc.ie/notifiablediseases/resources/epidemiologicalweeks/

TotalDailyVaccines Total Daily Vaccines

Gender Male

Female

NA

Dose Number Dose1 Dose 1

Dose2 Dose 2

SingleDose Single Dose

Vaccine Brand Moderna

Pfizer

Janssen

AstraZeneca

Age Group Partial_Age0to9 At Least One Dose Age 0 to 11 Dose 1 of Astrazenenca, MRNA or Single Dose Vaccine

Partial_Age10to19 At Least One Dose Age 12 to 19

Partial_Age20to29 At Least One Dose Age 20 to 29

Partial_Age30to39 At Least One Dose Age 30 to 39

Partial_Age40to49 At Least One Dose Age 40 to 49

Partial_Age50to59 At Least One Dose Age 50 to 59

Partial_Age60to69 At Least One Dose Age 60 to 69

Partial_Age70to79 At Least One Dose Age 70 to 79

Partial_Age80+ At Least One Dose Age80+

Partial_NA At Least One Dose Not Assigned

Age Group Cumulative ParCum_Age0to9 Cumulative Age 0 to 11 Cumulative At least One Dose Age 0 to 11

ParCum_Age10to19 Cumulative Age 12 to 19 Cumulative At least One Dose Age 12 to 19

ParCum_Age20to29 Cumulative Age 20 to 29 Cumulative At least One Dose Age 20 to 29

ParCum_Age30to39 Cumulative Age 30 to 39 Cumulative At least One Dose Age 30 to 39

ParCum_Age40to49 Cumulative Age 40 to 49 Cumulative At least One Dose Age 40 to 49

ParCum_Age50to59 Cumulative Age50 to 59 Cumulative At least One Dose Age 50 to 59

ParCum_Age60to69 Cumulative Age 60 to 69 Cumulative At least One Dose Age 60 to 69

ParCum_Age70to79 Cumulative Age 70 to 79 Cumulative At least One Dose Age 70 to 79

ParCum_80+ Cumulative Age 80+ Cumulative At least One Dose Age 80+

Age Group Cumulative Percent ParCum_NA Cumulative Age Not Assigned Cumulative At least One Dose Age Not Assigned

ParPer_Age0to9 At Least One Dose Percent Age 0 to 11 Cumulative At least One Dose Age cohort/ Age cohort population

ParPer_Age10to19 At Least One Dose Percent Age 12 to 19

ParPer_Age20to29 At Least One Dose Percent Age 20 to 29

ParPer_Age30to39 At Least One Dose Percent Age 30 to 39

ParPer_Age40to49 At Least One Dose Percent Age 40 to 49

ParPer_Age50to59 At Least One Dose Percent Age 50 to 59

ParPer_Age60to69 At Least One Dose Percent Age 60 to 69

ParPer_Age70to79 At Least One Dose Percent Age 70 to 79

ParPer_80+ At Least One Dose Percent 80+

ParPer_NA At Least One Dose Percent Not Assigned

Age Group Fully_Age0to9 Fully vaccinated Age 0 to 11 Dose 2 of An MRNA or AztraZeneca Vaccine or a single dose vaccine of a Janssen

Fully_Age10to19 Fully vaccinated Age 12 to 19

Fully_Age20to29 Fully vaccinated Age 20 to 29

Fully_Age30to39 Fully vaccinated Age 30 to 39

Fully_Age40to49 Fully vaccinated Age 40 to 49

Fully_Age50to59 Fully vaccinated Age 50 to 59

Fully_Age60to69 Fully vaccinated Age 60 to 69

Fully_Age70to79 Fully vaccinated Age 70 to 79

Fully_Age80+ Fully vaccinated Age 80+

Fully_NA Fully vaccinated Age Not Available

Age Group Cumulative FullyCum_Age0to9 Cumulative Fully vaccinated Age 0 to 11

FullyCum_Age10to19 Cumulative Fully vaccinated Age 12 to 19

FullyCum_Age20to29 Cumulative Fully vaccinated Age 20 to 29

FullyCum_Age30to39 Cumulative Fully vaccinated Age 30 to 39

FullyCum_Age40to49 Cumulative Fully vaccinated Age 40 to 49

FullyCum_Age50to59 Cumulative Fully vaccinated Age 50 to 59

FullyCum_Age60to69 Cumulative Fully vaccinated Age 60 to 69

FullyCum_Age70to79 Cumulative Fully vaccinated Age 70 to 79

FullyCum_80+ Cumulative Fully vaccinated Age 80+

Age Group Cumulative Percent FullyCum_NA Cumulative Fully vaccinated Age Not Available

FullyPer_Age0to9 Cumulative Percent Fully vaccinated Age 0 to 11 Cumulative Fully Vaccinated Age cohort/ Age cohort population

FullyPer_Age10to19 Cumulative Percent Fully vaccinated Age 12 to 19

FullyPer_Age20to29 Cumulative Percent Fully vaccinated Age 20 to 29

FullyPer_Age30to39 Cumulative Percent Fully vaccinated Age 30 to 39

FullyPer_Age40to49 Cumulative Percent Fully vaccinated Age 40 to 49

FullyPer_Age50to59 Cumulative Percent Fully vaccinated Age 50 to 59

FullyPer_Age60to69 Cumulative Percent Fully vaccinated Age 60 to 69

FullyPer_Age70to79 Cumulative Percent Fully vaccinated Age 70 to 79

FullyPer_80+ Cumulative Percent Fully vaccinated Age 80+

FullyPer_NA Cumulative Percent Fully vaccinated Age Not Available

Please see FAQ for latest information on COVID-19 Data Hub Data Flows https://covid-19.geohive.ie/pages/helpfaqs Field label Field Name Explanation Formula

ExtractDate Extract Date Date the data is Extracted

Latitude Latitude

Longitude Longitude

VaccinationDate Vaccination Date Date the Vaccination occurred

VaccineText Vaccine Date Text

AdditionalDose First Booster Dose The general population receiving their first booster dose of a vaccine

ImmunoDose Immunocompromised Dose Those who are immunocompromised receiving an extra dose as part of their primary course

AdditionalDoseCum First Booster Dose Cumulative

ImmunoDoseCum Immunocompromised Dose Cumulative

EligiblePop Population Over 5

PerBoosterDose % Population Boosted Percent of population over 5 with a first booster dose (First Booster Dose Cumulative/Population Over 5)*100

AdditionalDose2 Second Booster Dose The general population receiving a Second booster dose

ImmunoDose2 Second Immunocompromised Dose Those who are immunocompromised receiving an extra Immunocompromised dose

AdditionalDoseCum2 Second Booster Cumulative

ImmunoDoseCum2 Second Immunocompromised Dose Cumulative

EligiblePop2 Population Over 5

PerBoosterDose2 % Population Second Booster Percent of population over 5 with a second booster dose (Second Booster Dose Cumulative/Population Over 5)*100

Pairwise comparisons for the Irish (N = 1,030) and UK (N = 2,020) samples.

Correlates of class membership in the Irish sample (N = 1,030).

IntroductionGuidelines for the management of rheumatoid arthritis (RA) recommend using influenza and pneumococcal vaccinations to mitigate infection risk. The level of adherence to these guidelines is not well known in the UK. The aims of this study were to describe the uptake of influenza and pneumococcal vaccinations in patients with RA in the UK, to compare the characteristics of those vaccinated to those not vaccinated and to compare vaccination rates across regions of the UK.MethodsA retrospective cohort study of adults diagnosed with incident RA and treated with non-biologic immunosuppressive therapy, using data from a large primary care database. For the influenza vaccination, patients were considered unvaccinated on 1st September each year and upon vaccination their status changed to vaccinated. For pneumococcal vaccination, patients were considered vaccinated after their first vaccination until the end of follow-up. Patients were stratified by age 65 at the start of follow-up, given differences in vaccination guidelines for the general population.ResultsOverall (N = 15,724), 80% patients received at least one influenza vaccination, and 50% patients received a pneumococcal vaccination, during follow-up (mean 5.3 years). Of those aged below 65 years (N = 9,969), 73% patients had received at least one influenza vaccination, and 43% patients received at least one pneumococcal vaccination. Of those aged over 65 years (N = 5,755), 91% patients received at least one influenza vaccination, and 61% patients had received at least one pneumococcal vaccination. Those vaccinated were older, had more comorbidity and visited the GP more often. Regional differences in vaccination rates were seen with the highest rates in Northern Ireland, and the lowest rates in London.ConclusionsOne in five patients received no influenza vaccinations and one in two patients received no pneumonia vaccine over five years of follow-up. There remains significant scope to improve uptake of vaccinations in patients with RA.

This feature layer represents Sustainable Development Goal indicator 3.b.1 'Proportion of Population Covered by Vaccines by Type of Vaccine' for Ireland. The layer was created using Annual Epidemiological Report 2015 data produced by the Health Protection Surveillance Centre and pre 2014 Administrative County boundary data (more info) produced by Tailte Éireann. In 2015 UN countries adopted a set of 17 goals to end poverty, protect the planet and ensure prosperity for all as part of a new sustainable development agenda. Each goal has specific targets to help achieve the goals set out in the agenda by 2030. Governments are committed to establishing national frameworks for the achievement of the 17 Goals and to review progress using accessible quality data. With these goals in mind the Central Statistics Office (CSO) and Tailte Éireann are working together to link geography and statistics to produce indicators that help communicate and monitor Ireland’s performance in relation to achieving the 17 sustainable development goals.The indicator displayed supports the efforts to achieve goal number 3 which aims to ensure healthy lives and promote well-being for all at all ages.

Frequency and percentage of sample within occupation group by ethnic minority grouping.